<table>
<thead>
<tr>
<th>N°</th>
<th>TÍTULO</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>AUTOIMMUNE ENCEPHALITIS MEDIATED BY ANTI-N-METHYL-D-ASPARTATE ANTIBODIES IN PATIENTS WITH OVARIAN TERATOMA</td>
</tr>
<tr>
<td>64</td>
<td>DECIDUALIZATION MODULATES THE ANTIGEN PHENOTYPE AND CHEMOTACTIC ACTIVITY OF HUMAN DECIDUAL Stromal CELLS</td>
</tr>
<tr>
<td>84</td>
<td>COMPARACIÓN DE MEDICIÓN DE ANTICUERPOS DE ENFERMEDAD CELIACA POR ELISA CON ALBIA: NEOEPITOPO TRANSGLUTAMINASA IGA Y PEPTIDO DEAMIDADO DE GLIADINA IGG</td>
</tr>
<tr>
<td>123</td>
<td>ASSOCIATION BETWEEN MYOSITIS SPECIFIC OR ASSOCIATED ANTIBODIES AND IMMUNOFLUORESCENCE PATTERNS ON HEP-2000 CELLS</td>
</tr>
<tr>
<td>110</td>
<td>ANTI-NUCLEAR AUTOANTIBODY TESTING: LABORATORY EXPERIENCE</td>
</tr>
<tr>
<td>135</td>
<td>COMPARACION DE MEDICION DE ANTICUERPOS DE ENFERMEDAD CELIACA POR ELISA CON ALBIA. NEOEPITOPO TRANSGLUTAMINASA IGA Y PEPTIDO DEAMIDADO DE GLIADINA IGG</td>
</tr>
<tr>
<td>140</td>
<td>A CASE OF ENCEPHALITIS ASSOCIATED WITH LEUCINE RICH OSIOMA INACTIVATED 1 ANTIBODIES</td>
</tr>
<tr>
<td>158</td>
<td>ANCA-MPO ANTIBODIES OF IGA ISOTYPE IN ANCA ASSOCIATED VASCULITIS: PREVALENCE AND CLINICAL ASSOCIATIONS</td>
</tr>
<tr>
<td>61</td>
<td>ASSESSMENT AND MONITORING OF AUTOANTIBODIES IN IDIOPATHIC MEMBRANOUS NEPHROPATHY: RETROSPECTIVE STUDY IN A CORHOT OF PATIENTS</td>
</tr>
<tr>
<td>89</td>
<td>DEVELOPMENT OF AN ELISPOT ASSAY TO DETERMINE AND QUANTIFY SPECIFIC ANTI-DSDNA ANTIBODY SECRETING CELLS: A NOVEL BIOMARKER IN SYSTEMIC LUPUS ERYTHEMATOSUS</td>
</tr>
<tr>
<td>100</td>
<td>DECIDUALIZATION MODULATES THE ANTIGEN PHENOTYPE AND CHEMOTACTIC ACTIVITY OF HUMAN DECIDUAL Stromal CELLS</td>
</tr>
<tr>
<td>139</td>
<td>ASSOCIATION BETWEEN MYOSITIS SPECIFIC OR ASSOCIATED ANTIBODIES AND IMMUNOFLUORESCENCE PATTERNS ON HEP-2000 CELLS</td>
</tr>
<tr>
<td>154</td>
<td>EVALUATION OF TWO DISTINCT ASSAYS FOR DETECTION OF ANTI-TH/TO ANTIBODIES IN SYSTEMIC SCLEROSIS: A CROSS-SECTIONAL STUDY</td>
</tr>
<tr>
<td>202</td>
<td>ASSOCIATION BETWEEN APS/PT AUTOANTIBODIES AND LUPUS ANTICOAGULANT</td>
</tr>
<tr>
<td>210</td>
<td>CELLIAL DISEASE: INTEGRATING NEW METHODOLOGIES IN CURRENT DIAGNOSTIC STRATEGIES</td>
</tr>
<tr>
<td>211</td>
<td>ANCA-MPO ANTIBODIES OF IGA ISOTYPE IN ANCA ASSOCIATED VASCULITIS: PREVALENCE AND CLINICAL ASSOCIATIONS</td>
</tr>
<tr>
<td>212</td>
<td>KL6, A PROMISING BIOMARKER FOR INTERSTITIAL LUNG DISEASE. AN IMPORTANT TOOL FOR PATIENTS WITH CONNECTIVE TISSUE DISEASES</td>
</tr>
<tr>
<td>233</td>
<td>ASSESSMENT OF ANTI-GSTT1 ANTIBODIES IN TRANSPLANT PATIENTS AND THE EVALUATION OF THE AVAILABLE DIAGNOSTIC TOOLS.</td>
</tr>
<tr>
<td>242</td>
<td>EVALUATION OF TWO DISTINCT ASSAYS FOR DETECTION OF ANTI-TH/TO ANTIBODIES IN SYSTEMIC SCLEROSIS: A CROSS-SECTIONAL STUDY</td>
</tr>
<tr>
<td>256</td>
<td>MIXED CONNECTIVE TISSUE DISEASE AND ANTI-RNP AUTOANTIBODIES</td>
</tr>
<tr>
<td>262</td>
<td>NON-T CELL ACTIVATION LINKER (NTAL) EXPRESSION AS A REGULATOR OF ACTIVATORY INTRACELLULAR SIGNALS</td>
</tr>
<tr>
<td>279</td>
<td>NON-T CELL ACTIVATION LINKER (NTAL) EXPRESSION AS A REGULATOR OF ACTIVATORY INTRACELLULAR SIGNALS</td>
</tr>
<tr>
<td>284</td>
<td>LYMOPHOCYTE CHANGES INDUCED BY ALEMTUZUMAB IN MULTIPLE SCLEROSIS PATIENTS</td>
</tr>
<tr>
<td>291</td>
<td>ANTI-PHOSPHATIDYLISERINE/PROTHROMBIN ANTIBODIES ARE ASSOCIATED WITH EARLY MISCARRIAGES AND IMPLANTATION FAILURES IN OTHERWISE HEALTHY WOMEN</td>
</tr>
<tr>
<td>314</td>
<td>CLINICAL FEATURES IN PATIENTS WITH ANTI-MELANOMA DIFFERENTIATION-ASSOCIATED GENE 5 (ANTI-MDA5) ANTIBODIES</td>
</tr>
<tr>
<td>317</td>
<td>INTERACTIVE GUIDE OF AUTOIMMUNITY</td>
</tr>
</tbody>
</table>

**Sesión Autoinmunidad II.**

<table>
<thead>
<tr>
<th>N°</th>
<th>TÍTULO</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td>POLYGLANDULAR AUTOIMMUNE SYNDROMES IN CLINICAL PRACTICE-SINDROMES POLIGLANDULARES AUTOIMUNES EN LA PRACTICA CLINICA</td>
</tr>
<tr>
<td>22</td>
<td>EVIDENCE FOR AN EXPANDING SPECTRUM OF CLINICAL MANIFESTATIONS IN ANTI-NMDAR-POSITIVE PATIENTS</td>
</tr>
<tr>
<td>63</td>
<td>GRANULOCYTES FROM RHEUMATOID ARTHRITIS PATIENTS’ PERIPHERAL BLOOD SHOW A MATURE PHENOTYPE</td>
</tr>
<tr>
<td>113</td>
<td>RELEVANCE OF NON-CRITERIA ANTIPHOSPHOLIPID ANTIBODIES IN THE CLINICAL PRACTICE</td>
</tr>
<tr>
<td>147</td>
<td>IMMUNOBLOT ASSAY SPECIFICITY FOR ONCOEURAL AUTOANTIBODY DETECTION IN PARANEUROPLASTIC NEUROLOGICAL SYNDROMES (PNS)</td>
</tr>
<tr>
<td>154</td>
<td>EVALUATION OF MAULUMI 1000 CLIA AND DS2 AUTOANALYZERS IN THE MEASUREMENT OF ANTIBODIES AGAINST THE ANTIGEN TYROSINE PHOSPHATASE (1A2)</td>
</tr>
<tr>
<td>166</td>
<td>ASSESSMENT OF ANTI-GSTT1 ANTIBODIES IN TRANSPLANT PATIENTS AND THE EVALUATION OF THE AVAILABLE DIAGNOSTIC TOOLS.</td>
</tr>
<tr>
<td>196</td>
<td>IMMUNOMODULATORY DRUGS HUMANIZATION DOES NOT AVOID IMMUNOGENICITY</td>
</tr>
<tr>
<td>218</td>
<td>RETROSPECTIVE ANALYSIS OF THE INTRAEPITHELIAL LYMPHOCYTES PHENOTYPE IN A CORHOT OF PEDHATIC PATIENTS WITH CELIAC DISEASE</td>
</tr>
<tr>
<td>223</td>
<td>EVALUATION OF A CHEMILUMINESCENCE IMMUNOASSAY FOR THE DETECTION OF ANTI-PHOSPHOLIPID ANTIBODIES</td>
</tr>
<tr>
<td>242</td>
<td>RENTABILIDAD DIAGNÓSTICA DEL PROFIL DE MISOTIS EN UN HOSPITAL DE TERCER NIVEL</td>
</tr>
<tr>
<td>256</td>
<td>MIXED CONNECTIVE TISSUE DISEASE AND ANTI-RNP AUTOANTIBODIES</td>
</tr>
<tr>
<td>262</td>
<td>EVALUATION OF TWO DISTINCT ASSAYS FOR DETECTION OF ANTI-T/H/TO ANTIBODIES IN SYSTEMIC SCLEROSIS: A CROSS-SECTIONAL STUDY</td>
</tr>
<tr>
<td>279</td>
<td>NON-T CELL ACTIVATION LINKER (NTAL) EXPRESSION AS A REGULATOR OF ACTIVATORY INTRACELLULAR SIGNALS</td>
</tr>
<tr>
<td>284</td>
<td>LYMOPHOCYTE CHANGES INDUCED BY ALEMTUZUMAB IN MULTIPLE SCLEROSIS PATIENTS</td>
</tr>
<tr>
<td>291</td>
<td>ANTI-PHOSPHATIDYLISERINE/PROTHROMBIN ANTIBODIES ARE ASSOCIATED WITH EARLY MISCARRIAGES AND IMPLANTATION FAILURES IN OTHERWISE HEALTHY WOMEN</td>
</tr>
<tr>
<td>314</td>
<td>CLINICAL FEATURES IN PATIENTS WITH ANTI-MELANOMA DIFFERENTIATION-ASSOCIATED GENE 5 (ANTI-MDA5) ANTIBODIES</td>
</tr>
<tr>
<td>333</td>
<td>ASSESSMENT OF ANTI-GSTT1 ANTIBODIES IN TRANSPLANT PATIENTS AND THE EVALUATION OF THE AVAILABLE DIAGNOSTIC TOOLS.</td>
</tr>
</tbody>
</table>

**Comunicaciones Póster**
Sesión Inmunidad adaptativa e Hipersensibilidad.

81 THYMIC FUNCTION IMPACTS THE GUT MUCOSAL INTEGRITY OF HIV-INFECTED SUBJECTS
85 ROLE OF SSH-1 DURING T CELL ACTIVATION
107 COMPARISON OF MULTIPLEX AND SINGLEXPLEX ANALYSIS OF IGE SENSITIZATION IN PRIMARY CARE PATIENTS
112 DYNAMIC DISTRIBUTION OF PHOSPHATASE OF REGENERATING LIVER (PRL-3) AT THE IMMUNOLOGICAL SYNPASE
136 TRANSSEPHAGOCYTOSIS: A NOVEL MECHANISM FOR BACTERIAL UPTAKE BY B CELLS
224 CHARACTERIZATION OF AEROALLERGEN SENSITIVITIES IN POLYSENSITIZED PATIENTS IN CÁDIZ
248 EFFECTS OF MESENCHYMAL STEM CELLS (MSC) PURIFIED CD8 LYMPHOCYTES DEGRANULATION
313 IMMUNOLOGICAL BIOMARKERS DEFINING THE SENSITIZATION STATE TO HYMENOPTERA VENOM IN A COHORT OF ALLERGIC INDIVIDUALS
330 ADAPTIVE IMMUNE RESPONSE IN PATIENTS AFFECTED BY INFLAMMATORY BOWEL DISEASE UNDER TNF-TREATMENT

Sesión Inmunidad antitumoral.

15 TUMOR TARGETED THERAPY WITH GRANULYSIN-BASED IMMUNOTOXINS
18 FUNCTIONAL SYSTEMIC CD8 IMMUNITY IS REQUIRED FOR CLINICAL RESPONSES TO PD-L1/PD-1 BLOCKADE THERAPY
26 PHENOTYPIC AND FUNCTIONAL CHARACTERIZATION OF NK CELLS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
45 INTRATUMORAL DIVERSITY: SHAPING RESPONSE TO IMMUNE CHECKPOINT INHIBITORS
59 CANCER IMMUNOTHERAPY: BEYOND IMMUNE SYSTEM
74 INCREASED PD1 EXPRESSION IN T CD8 LYMPHOCYTES OF PATIENTS WITH GASTRIC ADENOCARCINOMA AND STUDY OF INFILTRATING CD8 AND PD1/PDL1 EXPRESSION IN GASTRIC TUMORS
92 TRANSFECTION WITH THE FHIT GENE PROMOTES HIGH IMMUNOGENICITY IN NEGATIVE MHC-I TUMOR CELLS
94 BACTERIA-TRAINED LYMPHOCYTES AS NEXT GENERATION OF CANCER IMMUNOTHERAPIES
105 LXR ACTIVATION AFFECTS THE GENE EXPRESSION PROFILE OF TUMOUR ASSOCIATED MACROPHAGES
139 ROLE OF IMMUNOLOGISTS AT THE NEW MULTIDISCIPLINARY UNITS OF HEMATOLOGICAL MALIGNANCIES ADVANCED TREATMENTS
150 OVERCOMING INTRINSICAL RESISTANCE TO PD1/PD1 MONOTHERAPIES IN NSCLC PATIENTS BY ANTI-PD1 & ANTILAG3 DUAL BLOCKADE
148 STUDY OF CALRETICULIN AS A POTENTIAL PROGNOSTIC BIOMARKER IN MULTIPLE MYELOMA
155 GENOMIC LOSS OF HLA ALLELES CHANGES THE CLINICAL OUTCOME IN LOW-RISK MYELODYSPLASTIC SYNDROME PATIENTS
199 A DUAL-TARGETED T CELL ENGAGER FOR CANCER IMMUNOTHERAPY
214 ACUTE LYMPHOBlastic LEUKEMIA AND CENTRAL NERVous SYstem INFLTRATION: IMPACT IN THE SUBVENTRICAL NEUROGENIC NICHE
220 MDSC EXPAND AFTER KIDNEY TRANSPLANTATION AND PREDICT DEVELOPMENT OF DE NOVO MALIGNANCIES
222 EXPRESSION AND MEANING OF IL2R CHAINS IN MDSC SUBSETS
274 IMMUNE CHECKPOINT T CELL ENGAGERS: A NEW CLASS OF ANTI-CANCER AGENTS
293 HETEROZYGOSTY OF HLA-C GROUP PREVENTS COLORECTAL CANCER WITH LOH FROM EVADING NK CYTOTOXICTY
294 COMPARATIVE ANALYSIS OF CELL SURFACE EXPRESSION OF HLA-A IN COLORECTAL CANCER CELL LINES AND CORRESPONDING PATIENT DERIVED XENOGRAFTS (PDX)
296 ANALYSIS OF HLA CLASS I EXPRESSION IN TUMOR CELLS DERIVED FROM PRIMARY COLORECTAL CANCER AND AUTOLOGOUS METASTASES
311 VACUNAS BASADAS EN LISTERIA COMO TERAPIA ANTI-TUMORAL
332 PD-L1 EXPRESSION IN SYSTEMIC IMMUNE CELL POPULATIONS AS POTENTIAL PREDICTIVE BIOMARKER OF RESPONSES TO PD-L1/PD-1 BLOCKADE THERAPY IN LUNG CANCER
Sesión Inmunidad Innata e inflamación.

2. COMPARATIVE MEASUREMENT OF COMPLEMENT SYSTEM (C3) BY TURBIDIMETRY.

10. HISPANOLONE DERIVATIVES AS NEW THERAPEUTIC AGENTS FOR TREATMENT OF RESPIRATORY DISEASES VIA MODULATION OF MACROPHAGE POLARIZATION.

39. INVOLVEMENT OF TLR4-MYD88 SIGNALLING AXIS IN LUNG MONOCYTIC ACTIVATION AND FUNCTION IN RESPONSE TO S. PNEUMONIAE.

45. IMMUNOMODULATORY EFFECTS OF MENSTRUAL BLOOD-DERIVED Stromal CELLS IN SEVERAL MODELS OF INFLAMMATION.

53. HUMAN ORAL EPITHELIAL CELLS MODULATE DC MATURATION AND IMPAIR T CELL RESPONSES BY MECHANISMS INSENSITIVE TO BACTERIAL STIMULATION.

67. IDENTIFICATION OF NOVEL ENDOPLASMIC RETICULUM STRESS PATHWAYS LINKED TO INFLAMMATORY BOWEL DISEASE.

69. DIFFERENTIAL POTENTIAL OF PRIMARY VERSUS MONOCYTE-DERIVED DCs ENHANCING FUNCTIONALITY OF NATURAL CELLS.

76. SYSTEMIC TLR2 AGONIST EXPOSURE PROTECTS MICE FROM CANDIDIASIS BY ACTIVATING HEMATOPOIETIC STEM AND PROGENITOR CELLS.

87. SIRT1 REPRESSES THE ABERRANT UPREGULATION OF PROINFLAMMATORY GENES THROUGH DNA HYPERMETHYLATION AND HISTONE III DEMETHYLATION IN M0 MACROPHAGES.

98. CHEMOTACTIC ACTIVITY OF HUMAN ENDOMETRIAL Stromal CELLS FROM ENDOMETRIUM AND ENDOMETRIOTIC FOCI ON LEUKOCYTES.

117. AGE-DEPENDENT INNATE IMMUNE CELL ACTIVATION IN THE CENTRAL NERVOUS SYSTEM OF MULTIPLE SCLEROSIS PATIENTS.

128. ICOS PLAYS A ROLE IN THE HOMEOSTASIS AND DEVELOPMENT OF NK CELLS.

130. ICOS AND ICOS-LIGAND INTERACTIONS IN NK CELL SIGNALING AND EFFECTOR FUNCTION.

132. SPEEDY DIAGNOSIS OF ANTIBODY DEFICIENCIES WITH THE MEASUREMENT OF SERUM-FREE LIGHT CHAINS.

136. SUPERHOMOZYGOUS TOLL (TOLL) EXPRESSION OF BLOOD DENDRITIC CELL POPULATIONS.

150. ROLE OF GALECTIN-1 IN CONTACT HYPERSENSITIVITY.

204. EFFECTS OF QUINOTONE ISOOTONIC SOLUTION ON HUMAN NEUTROPHILS.

225. DEFECT IN THE DECIDALIZATION OF HUMAN STRICT DECIDAL CELLS FROM DIFFERENT PARTNERS.

233. CD300A REDUCES NK CELLS EFFECTOR FUNCTIONS IN HIV-1 INFECTED PATIENTS.

241. DEEPLY IMMUNOPHETYPED PLAMACYTOID DENDRITIC CELL CHARACTERIZATION IN RESPONSE TO HIV-SPECIFIC TLR7 AND TLR9 LIGANDS.

244. DEEPLY IMMUNOPHETYPED PLAMACYTOID DENDRITIC CELL CHARACTERIZATION IN RESPONSE TO HIV-SPECIFIC TLR7 AND TLR9 LIGANDS.

250. AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME (ALPS): TWO NEW GERMLINE FRAME-SHIFT MUTATIONS IN THE FAS GENE.

252. POLARIZATION OF T HELPER RESPONSE IN ANTIBODY DEFICIENCIES.

303. DYSKERATOSIS CONGENITA: PRESENTATION, DIAGNOSIS AND CLINICAL MANAGEMENT.

307. EVALUATION OF POLYSACCHARIDE TYPHIM VI ANTIBODY RESPONSE AS A PREDICTOR OF HUMORAL IMMUNODEFICIENCY IN HAEMATOLOGICAL MALIGNANCIES.

Sesión Inmunodeficiencias.

28. CD300A REDUCES NK CELLS EFFECTOR FUNCTIONS IN HIV-1 INFECTED PATIENTS.

40. CD300A REDUCES NK CELLS EFFECTOR FUNCTIONS IN HIV-1 INFECTED PATIENTS.

46. CD300A REDUCES NK CELLS EFFECTOR FUNCTIONS IN HIV-1 INFECTED PATIENTS.

109. HLRBD: A COMPREHENSIVE DATABASE ON THE MOLECULAR BASIS OF PRIMARY HEMOPHAGOCYTIC LYMPHOPROLIFERATIVE SYNDROMES.

142. CHARACTERIZATION OF CD58null T-CELL SUBSETS DEFINED BY EXPRESSION OF CD45RA ISOLFORM IN HIV INFECTED PATIENTS.

151. EARLY ONSET TERTIARY DEFICIENCY (SDF) MAY IMPROVE AFTER ADOLESCENCE.

152. INCOMPLETE PENETRANCE IN ADULTS WITH X-LINKED AGAMMAGLOBULINEMIA DUE TO HYPOMOHRPHIC MUTATIONS IN BTK.

180. IMMUNoglobulin A (IgA) RECOVERY IN PREVIOUSLY DIAGNOSED WITH SELECTIVE IgA DEFICIENCY CHILDREN.

225. ACTI MUTATION ASSOCIATED WITH THE DEVELOPMENT OF CHRONIC MUCOCUTANEOUS CANDIDIASIS.

241. DIMINISHED CDS EXPRESSION IN AN ADULT PATIENT WITH RECURRENT PSEDERMA GANORENOIDES-LIKE LESIONS.

244. DEEPLY IMMUNOPHETYPED PLAMACYTOID DENDRITIC CELL CHARACTERIZATION IN RESPONSE TO HIV-SPECIFIC TLR7 AND TLR9 LIGANDS.

250. AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME (ALPS): TWO NEW GERMLINE FRAME-SHIFT MUTATIONS IN THE FAS GENE.

252. POLARIZATION OF T HELPER RESPONSE IN ANTIBODY DEFICIENCIES.

295. SPEEDY DIAGNOSIS OF ANTIBODY DEFICIENCIES WITH THE MEASUREMENT OF SERUM-FREE LIGHT CHAINS.

303. DYSKERATOSIS CONGENITA: PRESENTATION, DIAGNOSIS AND CLINICAL MANAGEMENT.

307. EVALUATION OF POLYSACCHARIDE TYPHIM VI ANTIBODY RESPONSE AS A PREDICTOR OF HUMORAL IMMUNODEFICIENCY IN HAEMATOLOGICAL MALIGNANCIES.
Nº Sesión Immunogenética.
58 HLA-G, A HAPLOTYPES IN AMERINDIANS (ECUADOR); HLA-G*01:05N WORLD DISTRIBUTION.
61 HLA GENES IN ATLANTIC CELTS POPULATIONS: ARE CELTS IBERIANS?
97 KILLER IMMUNOGLOBULIN-LIKE RECEPTOR (KIR) GENOTYPE DISTRIBUTION AMONGST PATIENTS WITH ACUTE MYELOID LEUKAEMIA
99 HUMAN LEUKOCYTE ANTIGEN (HLA) CLASS I AND II REPERTORY IN PATIENTS WITH ACUTE MYELOID LEUKAEMIA
125 ORIGIN OF AZERIS (IRAN) ACCORDING TO HLA GENES
126 HLA GENES IN BARRANQUILLA (NORTH COLOMBIA): SEARCHING FOR CRYPTIC AMERINDIAN GENES
189 IDENTIFICATION OF THREE NEW HLA ALLELES, HLA-B*56:55:01:02, -DRB1*01:99 AND -DPB1*13:01:03, BY NEXT GENERATION SEQUENCING.
191 THREE NEW HLA/C ALLELES, HLA-C*03:034, C*03:203 AND C*15:01:04, IDENTIFIED BY NEXT GENERATION SEQUENCING IN THE SPANISH POPULATION.
194 CHARACTERIZATION OF A NOVEL HLA ALLELE, C*05:199, GENERATED BY INTRALOCUS RECOMBINATION INVOLVING C*05:01:01:01 AND C*16:01:01:01 ALLELES.
215 IN CASE OF PATIENTS WITH RHEUMATIC DISEASE, COULD BE ASSOCIATED THEM WITH THE HLA-C LOCUS?
268 DISTRIBUTION OF KIR GENES AND THEIR CORRESPONDING HLA LIGAND IN BLOOD DONORS OF CATALONIA.
286 GENETIC STUDY IN A SPANISH COHORT OF NARCOLEPSY-TYPE 1 PATIENTS AND SUSCEPTIBILITY TO AUTOIMMUNE DISEASES.

Nº Sesión Terapias Avanzadas, Vacunas e Inmunidad anti-infectiosa.
3 IMMUNOGLOBULIN REPLACEMENT THERAPY IN A HOSPITAL UNIT OF MINORITY DISEASES.
7 REDUCTION IN ANTIDRUG ANTIBODY LEVELS AFTER SWITCHING TO RITUXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH PRIORTNF INHIBI.
104 OPTIMIZATION OF THERAPY WITH ECULIZUMAB.
145 B CELLS PROFILE AS A BIOMARKER FOR EARLY IDENTIFICATION OF OPTIMAL RESPONDERS TO TNF INHIBITORS IN RHEUMATOID ARTHRITIS.
183 THE UTILITY OF ELECTROFUGING IN THE FOLLOW-UP OF IgG MM PATIENTS TREATED WITH DARATUMUMAB.
190 REGULATION OF GENE AND PROTEIN EXPRESSION OF CRITICAL FACTORS IN THE ETIOLOGY OF COLO據 CANCER BY THE MICROSPORIDIA INFECTION.
192 CHANGES IN B CELL PROFILE AS A BIOMARKER FOR EARLY IDENTIFICATION OF OPTIMAL RESPONDERS TO TNF INHIBITORS IN PATIENTS WITH RHEUMATOID ARTHRITIS.
219 DIAGNOSIS OF INTESTINAL AND TISSUE MICROSPORIDIOSIS WITH A MONOCLONAL ANTIBODY AND ITS POSSIBLE IMMUNOTHERAPEUTIC ACTIVITY.
245 ANALYSIS OF ADAPTIVE NKCC1 - NK2A: NK LYMOPHOCYES IN DIFFERENT IMMUNOGENETIC CONTEXTS.
249 NEW THERAPEUTIC OPTION WITH MC/COAL AUTOVACCINE IN PATIENTS WITH SUPPURATIVE HIDRADENITIS.
302 RELATIONSHIP BETWEEN ELAPSED TIME FROM DELIVERY TO PROCESSING AND QUALITY OF UMBILICAL CORD BLOOD UNITS.

Nº Sesión Trasplantes.
5 RELATED HAPLOIDENTICAL DONORS VERSUS MATCHED UNRELATED DONORS.
20 POST-TRANSPLANT ACUTE KIDNEY INJURY IN RECIPIENTS WITH TUBULAR NECROSIS IS MEDIATED BY CD8 T CELLS.
23 STUDY OF B CELL MOLECULES IMPlicated ON ANTIHIV PRODUCTION IN KIDNEY TRANSPLANT: IS APRIL GENE POLYMORPHISM IMPORTANT?
71 CLINICAL RELEVANCE OF SPECIFIC DONOR ANTI-HLA ANTIBODIES IN HEART TRANSPLANTATION.
95 MANNOSE BINDING LECTIN (MBL2) MEASUREMENT AS RISK FACTOR OF VIRAL INFECTION IN SOLID ORGAN TRANSPLANT PATIENTS.
128 ASSESSMENT OF ANTI-GSTT1 ANTIBODIES IN TRANSPLANT PATIENTS AND THE EVALUATION OF THE AVAILABLE DIAGNOSTIC TOOLS.
130 HLA-B LOCSMismatch NUMBER AND RISK OF RENAL NEPHROPATHY RECURRENCE AFTER RENAL TRANSPLANTATION.
171 SEVERE COMPLEX SECONDARY IMMUNODEFICIENCY LATE AFTER SOLID ORGAN TRANSPLANTATION: AN EMERGING CLINICAL SETTING?
176 CLINICAL RELEVANCE OF SPECIFIC DONOR ANTI-HLA ANTIBODIES IN LIVER TRANSPLANTATION.
181 CHARACTERIZATION OF EPITOPES RECOGNIZED BY ANTIBODIES AGAINST HLA-DR IN PATIENT SERA FROM A KIDNEY TRANSPLANT WAITING LIST.
186 SHOULD REPEATED HLAMISMATCHES BE AVOIDED IN KIDNEY RE-TRANSPLANTATION?
193 CASE REPORT. ANTIBODY-MEDIATED REJECTION BY DONOR HLA-DR-SPECIFIC ANTIBODY.
301 PERIPHERAL BLOOD LYMOPHOCYTE SUBPOPULATIONS AFTER SMALL BOWEL PEDIATRIC TRANSPLANTATION.
312 ANTI-HLA ANTIBODY PROPERTIES DETECTED BY SOLID PHASE ASSAYS AND THEIR ASSOCIATION.